Topotecan in Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group

This publication has 10 references indexed in Scilit:

• A phase II study of irinotecan (CPT‐11) in patients with advanced squamous cell carcinoma of the cervix
  Cancer, 1998
• Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
  British Journal of Cancer, 1997
• Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
  Journal of Clinical Oncology, 1997
• Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
  Journal of Clinical Oncology, 1997
• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor
  British Journal of Cancer, 1996
• Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
  Journal of Clinical Oncology, 1995
• Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design
  JNCI Journal of the National Cancer Institute, 1994
• Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor
  JNCI Journal of the National Cancer Institute, 1993
• The Current Status of Camptothecin Analogues as Antitumor Agents
  JNCI Journal of the National Cancer Institute, 1993
• Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
  Journal of Clinical Oncology, 1985